9 completed. 6 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 6 |
| Phase 2 | 5 | Completed 5 |
Follow GTI2040: new trials by email Literature Review of GTI2040 trials Research Report on GTI2040
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination of GTI-2040 and Cytarabine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML) GTI-2040 - Acute Myeloid Leukemia | Phase 2 | Completed | Aptose Biosciences Inc. | 27 | 2007-08-01 | 2015-07-27 |
| GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia GTI-2040, pharmacological study, laboratory biomarker analysis - Acute Undifferentiated Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Phase 1 | Completed | National Cancer Institute (NCI) | 24 | 2007-03-01 | 2015-12-04 |
| GTI-2040, Docetaxel, and Prednisone in Treating Patients With Prostate Cancer GTI-2040, docetaxel, prednisone - Prostate Cancer | Phase 2 | Completed | University Health Network, Toronto | 22 | 2005-01-01 | 2021-04-28 |
| GTI-2040, Oxaliplatin, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer or Other Solid Tumors GTI-2040, oxaliplatin, capecitabine - Recurrent Colon Cancer, Recurrent Rectal Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 20 | 2004-05-01 | 2013-03-27 |
| GTI-2040 and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid Tumors GTI-2040, gemcitabine hydrochloride, laboratory biomarker analysis - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Completed | National Cancer Institute (NCI) | 40 | 2004-01-01 | 2013-01-24 |
| GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors GTI-2040, docetaxel, laboratory biomarker analysis - Recurrent Non-small Cell Lung Cancer, Recurrent Prostate Cancer | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 48 | 2003-10-01 | 2013-01-24 |
| GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast Cancer GTI-2040, capecitabine - Male Breast Cancer, Recurrent Breast Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 24 | 2003-10-01 | 2014-10-31 |
| GTI-2040 and High-Dose Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia GTI-2040, cytarabine, pharmacological study - Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Phase 1 | Completed | National Cancer Institute (NCI) | 51 | 2003-09-01 | 2013-06-04 |
| Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma GTI-2040 - Carcinoma, Renal Cell, Metastases, Neoplasm | Phase 1 / Phase 2 | Completed | Aptose Biosciences Inc. | 43 | 2002-03-01 | 2008-01-07 |
Leukemia, Myeloid, Acute (3) · Congenital Abnormalities (2) · Prostatic Neoplasms (2) · Blast Crisis (1) · Breast Neoplasms (1) · Breast Neoplasms, Male (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Colonic Neoplasms (1) · Leukemia, Biphenotypic, Acute (1) · Neoplasm Metastasis (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Rectal Neoplasms (1)
National Cancer Institute (NCI) (6) · Aptose Biosciences Inc. (2) · University Health Network, Toronto (1)
United States (7) · Canada (2)
Chris Takimoto (1) · Guido Marcucci (1) · Helen Chew (1) · Malcolm J. Moore, MD (1) · Mark Kirschbaum (1) · Natasha Leighl (1) · Rebecca B Klisovic, MD (1) · Stephen Shibata (1)
U01CA062505 (2), N01CM17107 (1), N01CM62209 (1), U01CA069853 (1), U01CA076576 (1)